Chimeric DNA vaccines against ErbB2+ carcinomas: From mice to humans

Cancers

Volumn 3, Issue 3, 2011, Pages 3225-3241

  Quaglino, Elena ^a   Riccardo, Federica ^a   Macagno, Marco ^a   Bandini, Silvio ^a   Cojoca, Rodica ^a   Ercole, Elisabetta ^a   Amici, Augusto ^b   Cavallo, Federica ^a  

^a UNIVERSITY OF TURIN   (Italy)

^b UNIVERSITY OF CAMERINO   (Italy)

Author keywords

DNA vaccines; ErbB2; Oncoantigens

Indexed keywords

CANCER VACCINE; DNA VACCINE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR VACCINE; INTERLEUKIN 2; PLASMID DNA; TRASTUZUMAB; TUMOR ANTIGEN;

BREAST CARCINOMA; BREAST TUMOR; CANCER GROWTH; CANCER IMMUNIZATION; CANCER PREVENTION; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURGERY; DNA IMMUNIZATION; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; ELECTROCHEMOTHERAPY; ELECTROPORATION; GENE OVEREXPRESSION; HUMAN; HYPOPHARYNX CANCER; IMMUNOLOGICAL TOLERANCE; LOW DRUG DOSE; MELANOMA; METASTASIS; MOLECULARLY TARGETED THERAPY; MOUTH CANCER; MULTIMODALITY CANCER THERAPY; NONHUMAN; OROPHARYNX CANCER; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN TARGETING; REVIEW;

EID: 80053211941     PISSN: None     EISSN: 20726694     Source Type: Journal    
DOI: 10.3390/cancers3033225     Document Type: Review

References (71)

1. Hanahan, D.; Weinberg RA. The hallmarks of cancer. Cell 2000, 100, 57-70.
2. Hanahan, D.; Weinberg, R.A. Hallmarks of cancer: the next generation. Cell 2011, 144, 646-674.
3. Cavallo, F.; De Giovanni, C.; Nanni, P.; Forni, G.; Lollini, P.L. 2011: The immune hallmarks of cancer. Cancer Immunol. Immunother. 2011, 60, 319-326.
4. Aldrich, J.F.; Lowe, D.B.; Shearer, M.H.; Winn, R.E.; Jumper, C.A.; Kennedy, R.C. Vaccines and immunotherapeutics for the treatment of malignant disease. Clin. Dev. Immunol. 2010, 2010, 697158.
5. Lollini, P.L.; Nicoletti, G.; Landuzzi, L.; Cavallo, F.; Forni, G.; De Giovanni, C.; Nanni, P. Vaccines and Other Immunological Approaches for Cancer Immunoprevention. Curr. Drug Targets 2010, 15 December 2010, PMID:21158706, Epub ahead of print.
6. Romero, P.; Cerottini, J.C.; Speiser, D.E. Monitoring tumor antigen specific T-cell responses in cancer patients and phase I clinical trials of peptide-based vaccination. Cancer Immunol. Immunother. 2004, 53, 249-255.
7. Allen, S.D.; Garrett, J.T.; Rawale, S.V.; Jones, A.L.; Phillips, G.; Forni, G.; Morris, J.C.; Oshima, R.G.; Kaumaya, P.T. Peptide vaccines of the HER-2/neu dimerization loop are effective in inhibiting mammary tumor growth in vivo. J. Immunol. 2007, 179, 472-482.
8. Melief, C.J.; van der Burg, S.H. Immunotherapy of established (pre)malignant disease by synthetic long peptide vaccines. Nat. Rev. Cancer 2008, 8, 351-360.
9. Sato, N.; Hirohashi, Y.; Tsukahara, T.; Kikuchi, T.; Sahara, H.; Kamiguchi, K.; Ichimiya, S.; Tamura, Y.; Torigoe, T. Molecular pathological approaches to human tumor immunology. Pathol. Int. 2009, 59, 205-217.
10. Sakai, Y.; Morrison, B.J.; Burke, J.D.; Park, J.M.; Terabe, M.; Janik, J.E.; Forni, G., Berzofsky, J.A.; Morris, J.C. Vaccination by genetically modified dendritic cells expressing a truncated neu oncogene prevents development of breast cancer in transgenic mice. Cancer Res. 2004, 64, 8022-8028.
11. Palucka, A.K.; Ueno, H.; Fay, J.; Banchereau, J. Endritic cells: A critical player in cancer therapy? J. Immunother. 2008, 31, 793-805.
12. Yamanaka, R. Dendritic-cell- and peptide-based vaccination strategies for glioma. Neurosurg. Rev. 2009, 32, 265-273.
13. Gallo, P.; Dharmapuri, S.; Nuzzo, M.; Maldini, D.; Cipriani, B.; Forni, G.; Monaci, P. Adenovirus vaccination against neu oncogene exerts long-term protection from tumorigenesis in BALB/neuT transgenic mice. Int. J. Cancer 2007, 120, 574-584.
14. + Th1 cells and antibodies in HER-2 adenovirus vaccine protection against autochthonous mammary carcinomas. J. Immunol. 2005, 174, 4228-4236.
15. Harrop, R.; Carroll, M.W. Viral vectors for cancer immunotherapy. Front. Biosci. 2006, 11, 804-817.
16. Cipriani, B.; Fridman, A.; Bendtsen, C.; Dharmapuri, S.; Mennuni, C.; Pak, I.; Mesiti, G.; Forni, G.; Monaci, P.; Bagchi, A.; Ciliberto, G.; La Monica, N.; Scarselli, E. Therapeutic vaccination halts disease progression in BALB-neuT mice: The amplitude of elicited immune response is predictive of vaccine efficacy. Hum. Gene Ther. 2008, 19, 670-680.
17. Park, J.M.; Terabe, M.; Steel, J.C.; Forni, G.; Sakai, Y.; Morris, J.C.; Berzofsky, J.A. Therapy of advanced established murine breast cancer with a recombinant adenoviral ErbB-2/neu vaccine. Cancer Res. 2008, 68, 1979-1987.
18. Wolff, J.A.; Malone, R.W.; Williams, P.; Chong, W.; Acsadi, G.; Jani, A.; Felgner, P.L. Direct gene transfer into mouse muscle in vivo. Science 1990, 247, 1465-1468.
19. Ulmer, J.B.; Donnelly, J.J.; Parker, S.E.; Rhodes, G.H.; Felgner, P.L.; Dwarki, V.J.; Gromkowski, S.H.; Deck, R.R.; DeWitt, C.M.; Friedman, A.; et al. Heterologous protection against influenza by injection of DNA encoding a viral protein. Science 1993, 259, 1745-1749.
20. Krieg, A.M. CpG motifs in bacterial DNA and their immune effects. Annu. Rev. Immunol. 2002, 20, 709-760.
21. Quaglino, E.; Iezzi, M.; Mastini, C.; Amici, A.; Pericle, F.; Di Carlo, E.; Pupa, S.M.; De Giovanni, C.; Spadaro, M.; Curcio, C.; Lollini, P.L.; Musiani, P.; Forni, G.; Cavallo, F. Electroporated DNA vaccine clears away multifocal mammary carcinomas in her-2/neu transgenic mice. Cancer Res. 2004, 64, 2858-2864.
22. Bodles-Brakhop, A.M.; Heller, R.; Draghia-Akli, R. Electroporation for the delivery of DNA-based vaccines and immunotherapeutics: Current clinical developments. Mol. Ther. 2009, 17, 585-592.
23. Rovero, S.; Amici, A.; Di Carlo, E.; Bei, R.; Nanni, P.; Quaglino, E.; Porcedda, P.; Boggio, K.; Smorlesi, A.; Lollini, P.L.; Landuzzi, L.; Colombo, M.P.; Giovarelli, M.; Musiani, P.; Forni, G. DNA Vaccination against rat Her-2/Neu p185 more effectively inhibits carcinogenesis than transplantable carcinomas in transgenic BALB/c mice. J. Immunol. 2000, 165, 5133-5142.
24. Quaglino, E.; Mastini, C.; Amici, A.; Marchini, C.; Iezzi, M.; Lanzardo, S.; De Giovanni, C.; Montani, M.; Lollini, P.L.; Masucci, G.; Forni, G.; Cavallo, F. A Better Immune Reaction to Erbb-2 Tumors Is Elicited in Mice by DNA Vaccines Encoding Rat/Human Chimeric Proteins. Cancer Res. 2010, 70, 2604-2612.
25. Jacob, J.B.; Quaglino, E.; Radkevich-Brown, O.; Jones, R.F.; Piechocki, M.P.; Reyes, J.D.; Weise, A.; Amici, A.; Wei, W.Z. Combining human and rat sequences in her-2 DNA vaccines blunts immune tolerance and drives antitumor immunity. Cancer Res. 2010, 70, 119-128.
26. Cavallo, F.; Offringa, R.; Van der Burg, S.H.; Forni, G.; Melief, C.J. Vaccination for treatment and prevention of cancer in animal models. Adv. Immunol. 2006, 90, 175-213.
27. Tighe, H.; Corr, M.; Roman, M.; Raz, E. Gene vaccination: plasmid DNA is more than just a blueprint. Immunol. Today 1998, 19, 89-97.
28. Roman, M.; Martin-Orozco, E.; Goodman, J.S.; Nguyen, M.D.; Sato, Y.; Ronaghy, A.; Kornbluth, R.S.; Richman, D.D.; Carson, D.A.; Raz, E. Immunostimulatory DNA sequences function as T helper-1-promoting adjuvants. Nat. Med. 1997, 3, 849-854.
29. Krieg, A.M. From bugs to drugs: therapeutic immunomodulation with oligodeoxynucleotides containing CpG sequences from bacterial DNA. Antisense Nucleic Acid Drug D. 2001, 11, 181-188.
30. Mastini, C.; Becker, P.D., Iezzi, M.; Curcio, C.; Musiani, P.; Forni, G.; Cavallo, F.; Guzmán, C.A. Intramammary application of non-methylated-CpG oligodeoxynucleotides (CpG) inhibits both local and systemic mammary carcinogenesis in female BALB/c Her-2/neu transgenic mice. Curr. Cancer Drug Targets 2008, 8, 230-242.
31. Lollini, P.L.; Cavallo, F.; Nanni, P.; Forni, G. Vaccines for tumour prevention. Nat. Rev. Cancer 2006, 6, 204-216.
32. Cavallo, F.; Calogero, R.A.; Forni, G. Are oncoantigens suitable targets for anti-tumour therapy? Nat. Rev. Cancer 2007, 7, 707-713.
33. Spears, M.; Taylor, K.J.; Munro, F.A.; Cunningham, C.A.; Mallon, E.A.; Twelves, C.J.; Cameron, D.A.; Thomas, J.; Bartlett, J.M.S. In situ detection of HER2:HER2 and HER2: HER3 proteinprotein interactions demonstrates prognostic significance in early breast cancer. Breast Cancer Res. Treat. 2011, doi: 10.1007/s10549-011-1606-z.
34. Quaglino, E.; Mastini, C.; Forni, G.; Cavallo, F. ErbB2 transgenic mice: a tool for investigation of the immune prevention and treatment of mammary carcinomas. Curr. Protoc. Immunol. 2008, doi: 10.1002/0471142735.im2009s82.
35. Disis, M.L.; Gralow, J.R.; Bernhard, H.; Hand, S.L.; Rubin, W.D.; Cheever, M.A. Peptide-based, but not whole protein, vaccines elicit immunity to HER-2/neu, oncogenic self-protein J. Immunol. 1996, 156, 3151-3158.
36. Curcio, C.; Di Carlo, E.; Clynes, R.; Smyth, M.J.; Boggio, K.; Quaglino, E.; Spadaro, M.; Colombo, M.P.; Amici, A.; Lollini, P.L.; Musiani, P.; Forni, G. Nonredundant roles of antibody, cytokines, and perforin in the eradication of established Her-2/neu carcinomas. J. Clin. Invest. 2003, 111, 1161-1670.
37. Curcio, C.; Khan, A.S.; Amici, A.; Spadaro, M.; Quaglino, E.; Cavallo, F.; Forni, G.; Draghia-Akli, R. DNA immunization using constant-current electroporation affords long-term protection from autochthonous mammary carcinomas in cancer-prone transgenic mice. Cancer Gene Ther. 2008, 15, 108-114.
38. Bibby, M.C. Orthotopic models of cancer for preclinical drug evaluation: advantages and disadvantages. Eur. J. Cancer 2004, 40, 852-857.
39. Dunn, G.P.; Old, L.J.; Schreiber, R.D. The three Es of cancer immunoediting. Annu. Rev. Immunol. 2004, 22, 329-360.
40. Kamb, A. What's wrong with our cancer models? Nat. Rev. Drug Discov. 2005, 4, 161-165.
41. Ostrand-Rosemberg, S. Animal models of tumor immunity, immunotherapy and cancer vaccines. Curr. Opin. Immunol. 2004, 171, 143-150.
42. Lollini, P.L.; De Giovanni, C.; Pannellini, T.; Cavallo, F.; Forni, G.; Nanni, P. Cancer immunoprevention. Future Oncol. 2005, 1, 57-66.
43. Rolla, S.; Nicoló, C.; Malinarich, S.; Orsini, M.; Forni, G.; Cavallo, F.; Ria, F. Distinct and non-overlapping T cell receptor repertoires expanded by DNA vaccination in wild-type and HER-2 transgenic BALB/c mice. J. Immunol. 2006, 177, 7626-7633.
44. Rolla, S.; Ria, F.; Occhipinti, S.; Di Sante, G.; Iezzi, M.; Spadaro, M.; Nicolò, C.; Ambrosino, E.; Merighi, I.F.; Musiani, P.; Forni, G.; Cavallo, F. Erbb2 DNA vaccine combined with regulatory T cell deletion enhances antibody response and reveals latent low-avidity T cells: Potential and limits of its therapeutic efficacy. J. Immunol. 2010, 184, 6124-6132.
45. Piechocki, M.P.; Ho, Y.S.; Pilon, S.; Wei, W.Z. Human ErbB-2 (Her-2) transgenic mice: a model system for testing Her-2 based vaccines. J. Immunol. 2003, 171, 5787-5794.
46. Boggio, K.; Nicoletti, G.; Di Carlo, E.; Cavallo, F.; Landuzzi, L.; Melani, C.; Giovarelli, M.; Rossi, I.; Nanni, P.; De Giovanni, C.; Bouchard, P.; Wolf, S.; Modesti, A.; Musiani, P.; Lollini, P.L.; Colombo, M.P.; Forni, G. Interleukin 12-mediated prevention of spontaneous mammary adenocarcinomas in two lines of Her-2/neu transgenic mice. J. Exp. Med. 1998, 188, 589-596.
47. Pannellini, T.; Forni, G.; Musiani, P. Immunobiology of her-2/neu transgenic mice. Breast Dis. 2004, 20, 33-42.
48. Finkle, D.; Quan, Z.R.; Asghari, V.; Kloss, J.; Ghaboosi, N.; Mai, E.; Wong, W.L.; Hollingshead, P.; Schwall, R.; Koeppen, H.; Erickson, S. HER2-targeted therapy reduces incidence and progression of midlife mammary tumors in female murine mammary tumor virus huHER2-transgenic mice. Clin. Cancer Res. 2004, 10, 2499-2511.
49. Hüsemann, Y.; Geigl, J.B.; Schubert, F.; Musiani, P.; Meyer, M.; Burghart, E.; Forni, G.; Eils, R.; Fehm, T.; Riethmüller, G.; Klein, C.A. Systemic spread is an early step in breast cancer. Cancer Cell 2008, 13, 58-68.
50. Ambrosino, E.; Spadaro, M.; Iezzi, M.; Curcio, C.; Forni, G.; Musiani, P.; Wei, W.Z.; Cavallo, F. Immunosurveillance of Erbb2 Carcinogenesis in Transgenic Mice Is Concealed by a Dominant Regulatory T-Cell Self-Tolerance. Cancer Res. 2006, 66, 7734-7740.
51. Melani, C.; Chiodoni, C.; Forni, G.; Colombo, M.P. Myeloid cell expansion elicited by the progression of spontaneous mammary carcinomas in c-erbB-2 transgenic BALB/c mice suppresses immune reactivity. Blood 2003, 102, 2138-2145.
52. Disis, M.L.; Calenoff, E.; McLaughlin, G.; Murphy, A.E.; Chen, W.; Groner, B.; Jeschke, M.; Lydon, N.; McGlynn, E.; Livingston, R.B.; et al. Existent T cell and antibody immunity to Her-2/neu protein in patients with breast cancer. Cancer Res. 1994, 54, 16-20.
53. Peoples, G.E.; Blotnick, S.; Takahashi, K.; Freeman, M.R.; Klagsbrun, M.; Eberlein, T.J. T lymphocytes that infiltrate tumors and atherosclerotic plaques produce heparin-binding epidermal growth factor-like growth factor and basic fibroblast growth factor: a potential pathologic role. Proc. Natl. Acad. Sci. USA 1995, 92, 6547-6551.
54. Babiuk, S.; Baca-Estrada, M.E.; Foldvari, M.; Storms, M.; Rabussay, D.; Widera, G.; Babiuk, L.A. Electroporation improves the efficacy of DNA vaccines in large animals. Vaccine 2002, 20, 3399-3408.
55. Luxembourg, A.; Hannaman, D.; Nolan, E.; Ellefsen, B.; Nakamura, G.; Chau, L.; Tellez, O.; Little, S.; Bernard, R. Potentiation of an anthrax DNA vaccine with electroporation. Vaccine 2008, 26, 5216-5222.
56. Liu, K.H.; Ascenzi, M.A.; Bellezza, C.A.; Bezuidenhout, A.J.; Cote, P.J.; Gonzalez-Aseguinolaza, G.; Hannaman, D.; Luxembourg, A.; Evans, C.F.; Tennant, B.C.; Menne, S. Electroporation enhances immunogenicity of a DNA vaccine expressing woodchuck hepatitis virus surface antigen in woodchucks. J. Virol. 2011, 85, 4853-4862.
57. Engelhorn, M.E.; Guevara-Patiño, J.A.; Noffz, G.; Hooper, A.T.; Lou, O.; Gold, J.S.; Kappel, B.J.; Houghton, A.N. Autoimmunity and tumor immunity induced by immune responses to mutations in self. Nat. Med. 2006, 12, 198-206.
58. Fattori, E.; Aurisicchio, L.; Zampaglione, I.; Arcuri, M.; Cappelletti, M.; Cipriani, B.; Mennuni, C.; Calvaruso, F.; Nuzzo, M.; Ciliberto, G.; et al. Her2/neu genetic cancer vaccine in non human primates: relevance of single nucleotide polymorphisms. Hum. Gene Ther. 2008, 8 December 2008, PMID:19061436, Epub ahead of print.
59. + T cell precursor frequency determines the quality of the antitumor immune response. J. Exp. Med. 2009, 206, 849-866.
60. Jacob, J.; Radkevich, O.; Forni, G.; Zielinski, J.; Shim, D.; Jones, R.F.; Wei, W-Z. Activity of DNA vaccines encoding self or heterologous Her-2/neu in Her-2 or neu transgenic mice. Cell Immunol. 2006, 240, 96-106.
61. Norrel, H.; Poschke, I.; Charo, J., Wei, W.Z.; Erskine, C.; Piechocki, M.; Knutson, K.; Bergh, J.; Lidbrink, E.; Kiessling, R. Vaccination with a plasmid DNA encoding HER-2/neu together with low doses with metastaic breast carcinoma: a pilot clinical trial. J. Transl. Med. 2010, 8, 1-11.
62. Frelin, L.; Brass, A.; Ahlén, G.; Brenndörfer, E.D.; Chen, M.; Sällberg, M. Electroporation: A promising method for the nonviral delivery of DNA vaccines in humans? Drug News Perspect. 2010, 23, 647-653.
63. Luxembourg, A.; Evans, C.F.; Hannaman, D. Electroporation-based DNA immunisation: translation to the clinic. Expert Opin. Biol. Ther. 2007, 7, 1647-1664.
64. Mir, L.M. Application of electroporation gene therapy: past, current, and future. Methods Mol. Biol. 2008, 423, 3-17.
65. Gehl, J. Electroporation for drug and gene delivery in the clinic: Doctors go electric. Methods Mol. Biol. 2008, 423, 351-359.
66. Mir, L.M.; Morsli, N.; Garbay, J.R.; Billard, V.; Robert, C.; Marty, M. Electrochemotherapy: A new treatment of solid tumors. J. Exp. Clin. Cancer Res. 2003, 22, 145-148.
67. Colombo, G.L.; Matteo, S.D.; Mir, L.M. Cost-effectiveness analysis of electrochemotherapy with the Cliniporator™ vs other methods for the control and treatment of cutaneous and subcutaneous tumors. Ther. Clin. Risk Manag. 2008, 4, 541-548.
68. Quaglino, P.; Mortera, C.; Osella-Abate, S.; Barberis, M.; Illengo, M.; Rissone, M.; Savoia, P.; Bernengo, M.G. Electrochemotherapy with intravenous bleomycin in the local treatment of skin melanoma metastases. Ann. Surg. Oncol. 2008, 15, 2215-2222.
69. Jaroszeski, M.J.; Coppola, D.; Nesmith, G.; Pottinger, C.; Hyacinthe, M.; Benson, K.; Gilbert, R.; Heller, R. Effects of electrochemotherapy with bleomycin on normal liver tissue in a rat model. Eur. J. Cancer 2001, 37, 414-421.
70. Gehl, J.; Sorensen, T.H.; Nielsen, K.; Raskmark, P.; Nielsen, S.L.; Skovsgaard, T.; Mir, L.M. In vivo electroporation of skeletal muscle: Threshold, efficacy and relation to electric field distribution. Biochim. Biophys. Acta 1999, 1428, 233-240.
71. Abate-Shen, C. A new generation of mouse models of cancer for translational research. Clin. Cancer Res. 2006, 12, 5274-5276.